research use only

Tivantinib c-Met inhibitor

Name: Tivantinib
Brand: Selleck Chemicals
SKU: S2753
Availability: InStock
Rating: 5 (49 reviews)

Cat.No.S2753

Tivantinib is the first non-ATP-competitive c-Met inhibitor with K_i of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. This compound induces a G2/M arrest and apoptosis.

Chemical Structure

Molecular Weight: 369.42

Jump to

Quality Control

Batch: Purity: 99.65%

99.65

Related Targets	EGFR VEGFR PDGFR FGFR Src MEK CSF-1R FLT3 HER2 c-Kit
Other c-Met Inhibitors	Tepotinib Dihexa SGX-523 PHA-665752 Foretinib SU11274 BMS-777607 JNJ-38877605 PF-04217903 Savolitinib (AZD6094)

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Formulation	Activity Description
MNK-45	Kinase assay	~10 μM		inhibits c-Met phosphorylation and downstream c-Met signaling pathways
HT29	Kinase assay	~10 μM		inhibits c-Met phosphorylation and downstream c-Met signaling pathways
MDA-MB-231	Kinase assay	~10 μM		inhibits c-Met phosphorylation and downstream c-Met signaling pathways
NCI-H441	Kinase assay	~10 μM		inhibits c-Met phosphorylation and downstream c-Met signaling pathways
SK-MEL-28	Growth inhibitory assay	33 μM		IC50>33 μM
NCI-H661	Growth inhibitory assay	33 μM		IC50>33 μM
NCI-H446	Growth inhibitory assay	33 μM		IC50=7 μM
MDA-MB-231	Growth inhibitory assay	33 μM		IC50=0.55 μM
DLD-1	Growth inhibitory assay	33 μM		IC50=0.53 μM
A549	Growth inhibitory assay	33 μM		IC50=0.59 μM
SK-OV-3	Growth inhibitory assay	33 μM		IC50=0.66 μM
NCI-H460	Growth inhibitory assay	33 μM		IC50=0.6 μM
A375	Growth inhibitory assay	33 μM		IC50=0.42 μM
NCI-H441	Growth inhibitory assay	33 μM		IC50=0.3 μM
HT29	Growth inhibitory assay	33 μM		IC50=0.49 μM
MKN-45	Growth inhibitory assay	33 μM		IC50=0.58 μM
HT29	Apoptosis assay	~10 μM		significantly induces apoptosis by 80-90%.
MKN-45	Apoptosis assay	~10 μM		significantly induces apoptosis by 80-90%.
MDA-MB-231	Apoptosis assay	~10 μM		modestly induces apoptosis by 35%.
MDA-MB-231/TGL	Growth inhibitory assay	~100 μM		GI50=1.2 μM
1833/TGL	Growth inhibitory assay	~100 μM		GI50=3.7 μM
EBC1	Cytotoxic assay	~10 μM		inhibits the cell growth.
SNU638	Cytotoxic assay	~10 μM		inhibits the cell growth.
A549	Cytotoxic assay	~10 μM		not affect
H460	Cytotoxic assay	~10 μM		not affect
HCC827	Cytotoxic assay	~10 μM		not affect
A549	Function assay	10 μM		disrupts microtubule
EBC1	Function assay	10 μM		disrupts microtubule
H460	Function assay	10 μM		inhibits tubulin polymerization
K562/VCR	Cytotoxic assay	~10 μM		shows cytotoxic activity
CEM/VBL	Cytotoxic assay	~10 μM		shows cytotoxic activity
U266	Cytotoxic assay	~3 μM		IC50=1.1 μM
OPM-2	Cytotoxic assay	~3 μM		IC50=1.8 μM
MM.1S	Cytotoxic assay	~3 μM		IC50=1.6 μM
MM.1R	Growth inhibitory assay	3 μM		inhibits cell growth by 49%
RPMI-8226	Cytotoxic assay	~3 μM		IC50=0.9 μM
ANBL-6	Cytotoxic assay	1 μM		induces cell death by more than 50%
ANLB-6/V10R	Cytotoxic assay	1 μM		induces cell death by more than 50%
KAS-6/1	Cytotoxic assay	1 μM		induces cell death by more than 50%
KAS-6/V10R	Cytotoxic assay	1 μM		induces cell death by more than 50%
KAS-6/R10R	Cytotoxic assay	1 μM		induces cell death by more than 50%
8226/S	Growth inhibitory assay	3 μM		inhibits cell growth by 54%
8226/LR-5	Growth inhibitory assay	3 μM		inhibits cell growth by 54%
Huh7	Cytotoxic assay	~4.8 μM	DMSO	IC50=9.9 nM
Hep3B	Cytotoxic assay	~4.8 μM	DMSO	IC50=448.7 nM
HepG2	Cytotoxic assay	~4.8 μM	DMSO	IC50=139.77 nM
Chang	Cytotoxic assay	~4.8 μM	DMSO	IC50=448.7 nM
Huh7	Function assay	1.6 μM	DMSO	causes a G2/M cell cycle arrest
Hep3B	Function assay	1.6 μM	DMSO	causes a G2/M cell cycle arrest
HepG2	Function assay	1.6 μM	DMSO	causes a G2/M cell cycle arrest
Chang	Function assay	1.6 μM	DMSO	causes a G2/M cell cycle arrest
MHCC97L	Growth inhibitory assay	~10 μM	DMSO	IC50=315 nM
MHCC97H	Growth inhibitory assay	~10 μM	DMSO	IC50=368 nM
Huh7	Growth inhibitory assay	~10 μM	DMSO	IC50=265 nM
HepG2	Growth inhibitory assay	~10 μM	DMSO	IC50=392 nM
MHCC97L	Function assay	1 μM	DMSO	induces microtubules depolymerization
Huh7	Function assay	1 μM	DMSO	induces microtubules depolymerization
MHCC97L	Apoptosis assay	1 μM	DMSO	induces apoptosis
Huh7	Apoptosis assay	1 μM	DMSO	induces apoptosis
C3H 10T1/2 mouse fibroblasts	Kinase assay	25 μM	DMSO	reduces Histone H3 and H4 acetylation levels
H23	Growth inhibitory assay	25 μM	DMSO	significantly inhibits cell growth.
WM35	Growth inhibitory assay	10 μM	DMSO	significantly inhibits cell growth.
NIH 3T3	Growth inhibitory assay	10 μM	DMSO	does not have a significant inhibitory effect
H838	Growth inhibitory assay	10 μM	DMSO	does not have a significant inhibitory effect
H1395	Growth inhibitory assay	10 μM	DMSO	does not have a significant inhibitory effect
Quiescent S2	Kinase assay	30 μM	DMSO	completely abrogates TSA-induced hyperacetylation of H3K4me3 histones
PC3	Apoptosis assay	20 μM	DMSO	induces apoptosis
Du145	Apoptosis assay	20 μM	DMSO	induces apoptosis
LNCaP	Apoptosis assay	20 μM	DMSO	induces apoptosis
LAPC-4	Apoptosis assay	20 μM	DMSO	induces apoptosis
LNCaP	Function assay	20 μM	DMSO	decreases PSA secretion and p65 expression levels
LAPC-4	Function assay	20 μM	DMSO	decreases PSA secretion and p65 expression levels
Kasumi-1	Growth inhibitory assay	~50 μM	DMSO	inhibits cell proliferation
SKNO-1	Growth inhibitory assay	~50 μM	DMSO	inhibits cell proliferation
Kasumi-1	Kinase assay	~10 μM	DMSO	reduces expression of acetylated histone H3, c-kit and bcl-2
SKNO-1	Kinase assay	~10 μM	DMSO	reduces expression of acetylated histone H3, c-kit and bcl-2
A549	Function assay	10 μM	DMSO	enhances mitotic catastrophe
NRK-52E	Function assay	10 μM	DMSO	inhibits Ang II-induced STAT3 nuclear translocation and the expression of TGF-β1, collagen IV and fibronectin
PC12	Growth inhibitory assay	~12.5 μM	DMSO	prevents TSA-induced neurite formation
HPMCs	Function assay			reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells
A549	Function assay	~50 μM	DMSO	affects the viral life cycle and host response
RAW264.7	Function assay	~30 μM	DMSO	reduces pro-inflammatory gene expression
MEMM	Kinase assay	15 µM	DMSO	decreases acetylation of histone H3
MEMM	Growth inhibitory assay	~20 µM	DMSO	inhibits cell proliferation
MEMM	Apoptosis assay	15 µM	DMSO	induces the presence of the apoptosis protein, cleaved Caspase-3
T47D	Growth inhibitory assay	10 μM	DMSO	IC50=72 nM
ZR-75-1	Growth inhibitory assay	10 μM	DMSO	IC50=79 nM
BT474	Growth inhibitory assay	10 μM	DMSO	IC50=86 nM
HCC1954	Growth inhibitory assay	10 μM	DMSO	IC50=119 nM
MDA-MB-453	Growth inhibitory assay	10 μM	DMSO	IC50=975 nM
MDA-MB-468	Growth inhibitory assay	10 μM	DMSO	IC50=3208 nM
SkBr3	Growth inhibitory assay	10 μM	DMSO	IC50>10,000 nM
MDA-MB-231	Growth inhibitory assay	10 μM	DMSO	IC50>10,000 nM
HCT116	Growth inhibitory assay	10 μM	DMSO	IC50=5836 nM
HT29	Growth inhibitory assay	10 μM	DMSO	IC50>10,000 nM
HFF	Growth inhibitory assay	10 μM	DMSO	IC50=7615 nM
HN5	Growth inhibitory assay	10 μM	DMSO	IC50>10,000 nM
786-0	Growth inhibitory assay	10 μM	DMSO	IC50=4009 nM
H157	Growth inhibitory assay	10 μM	DMSO	IC50=2642 nM
NCI-H460	Growth inhibitory assay	10 μM	DMSO	IC50>2,500 nM
SKOV-3	Growth inhibitory assay	10 μM	DMSO	IC50=2126 nM
OVCAR-3	Growth inhibitory assay	10 μM	DMSO	IC50=2918 nM
BXPC3	Growth inhibitory assay	10 μM	DMSO	IC50=3141 nM
MiaPaCa	Growth inhibitory assay	10 μM	DMSO	IC50=5433 nM
PANC-1	Growth inhibitory assay	10 μM	DMSO	IC50=8681 nM
LNCaP	Growth inhibitory assay	10 μM	DMSO	IC50=147 nM
DU145	Growth inhibitory assay	10 μM	DMSO	IC50=3812 nM
PC3	Growth inhibitory assay	10 μM	DMSO	IC50>10,000 nM
BT474	Kinase assay	10 μM	DMSO	inhibits pGSK3β with IC50 of 160 nM
786-0	Kinase assay	10 μM	DMSO	inhibits pGSK3β with IC50 of 150 nM
LNCaP	Kinase assay	10 μM	DMSO	inhibits pGSK3β with IC50 of 43 nM
PC3	Kinase assay	10 μM	DMSO	inhibits pGSK3β with IC50 of 49 nM
KARPAS-231	Growth inhibitory assay	10 μM	DMSO	EC50=41 nM
CCRFSB	Growth inhibitory assay	10 μM	DMSO	EC50=155 nM
SUP B15	Growth inhibitory assay	10 μM	DMSO	EC50=197 nM
SD-1	Growth inhibitory assay	10 μM	DMSO	EC50=320 nM
RS4;11	Growth inhibitory assay	10 μM	DMSO	EC50=654 nM
MN-60	Growth inhibitory assay	10 μM	DMSO	EC50=3602 nM
Tanoue	Growth inhibitory assay	10 μM	DMSO	EC50=4517 nM
RCH-ACV	Growth inhibitory assay	10 μM	DMSO	EC50=152 nM
SEM	Growth inhibitory assay	10 μM	DMSO	EC50=202 nM
KASUMI-2	Growth inhibitory assay	10 μM	DMSO	EC50=225 nM
REH	Growth inhibitory assay	10 μM	DMSO	EC50=288 nM
697	Growth inhibitory assay	10 μM	DMSO	EC50=338 nM
NALM-6	Growth inhibitory assay	10 μM	DMSO	EC50=421 nM
MHH-CALL–3	Growth inhibitory assay	10 μM	DMSO	EC50=812 nM
MHH-CALL–2	Growth inhibitory assay	10 μM	DMSO	EC50=2114 nM
J.GAMMA-1	Growth inhibitory assay	10 μM	DMSO	EC50=65 nM
JR45.01	Growth inhibitory assay	10 μM	DMSO	EC50=68 nM
A3	Growth inhibitory assay	10 μM	DMSO	EC50=69 nM
I 2.1	Growth inhibitory assay	10 μM	DMSO	EC50=73 nM
MOLT-3	Growth inhibitory assay	10 μM	DMSO	EC50=74 nM
P116	Growth inhibitory assay	10 μM	DMSO	EC50=78 nM
J.Cam1.6	Growth inhibitory assay	10 μM	DMSO	EC50=79 nM
I 9.2	Growth inhibitory assay	10 μM	DMSO	EC50=80 nM
LOUCY	Growth inhibitory assay	10 μM	DMSO	EC50=117 nM
J.RT3-T3.5	Growth inhibitory assay	10 μM	DMSO	EC50=123 nM
800000	Growth inhibitory assay	10 μM	DMSO	EC50=163 nM
Jurkat	Growth inhibitory assay	10 μM	DMSO	EC50=225 nM
MOLT-4	Growth inhibitory assay	10 μM	DMSO	EC50=232 nM
Molt-16	Growth inhibitory assay	10 μM	DMSO	EC50=241 nM
CEM/C3	Growth inhibitory assay	10 μM	DMSO	EC50=257 nM
CEM/C2	Growth inhibitory assay	10 μM	DMSO	EC50=271 nM
CCRFCEM	Growth inhibitory assay	10 μM	DMSO	EC50=327 nM
CEM/C1	Growth inhibitory assay	10 μM	DMSO	EC50=382 nM
SUPTI[VB]	Growth inhibitory assay	10 μM	DMSO	EC50=619 nM
CCRF–HSB-2	Growth inhibitory assay	10 μM	DMSO	EC50=2117 nM
I 2.1	Apoptosis assay	10 μM	DMSO	induces apoptosis
I 9.2	Apoptosis assay	10 μM	DMSO	induces apoptosis
A3	Apoptosis assay	10 μM	DMSO	induces apoptosis
RD	Growth inhibitory assay	10 μM		IC50>10 μM
Rh41	Growth inhibitory assay	10 μM		IC50=33.8 nM
Rh18	Growth inhibitory assay	10 μM		IC50=303 nM
Rh30	Growth inhibitory assay	10 μM		IC50=4.81 μM
BT-12	Growth inhibitory assay	10 μM		IC50>10 μM
CHLA-266	Growth inhibitory assay	10 μM		IC50=1.22 μM
TC-71	Growth inhibitory assay	10 μM		IC50=2.52 μM
CHLA-9	Growth inhibitory assay	10 μM		IC50=591 nM
CHLA-10	Growth inhibitory assay	10 μM		IC50=102 nM
CHLA-258	Growth inhibitory assay	10 μM		IC50=1.05 μM
GBM2	Growth inhibitory assay	10 μM		IC50=9.15 μM
NB-1643	Growth inhibitory assay	10 μM		IC50=5.4 μM
NB-Ebc1	Growth inhibitory assay	10 μM		IC50>10 μM
CHLA-90	Growth inhibitory assay	10 μM		IC50>10 μM
CHLA-136	Growth inhibitory assay	10 μM		IC50>10 μM
NALM-6	Growth inhibitory assay	10 μM		IC50=265 nM
COG-LL-317	Growth inhibitory assay	10 μM		IC50=6.49 nM
RS4;11	Growth inhibitory assay	10 μM		IC50=147 nM
MOLT-4	Growth inhibitory assay	10 μM		IC50=40 nM
CCRF-CEM	Growth inhibitory assay	10 μM		IC50=268 nM
Kasumi-1	Growth inhibitory assay	10 μM		IC50=107 nM
Karpas-299	Growth inhibitory assay	10 μM		IC50=2.93 μM
Ramos-RA1	Growth inhibitory assay	10 μM		IC50=7.35 μM
H1299	Kinase assay	10 μM		inhibits IKBKE-induced Akt Activation
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 73 mg/mL (197.6 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 35 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.500mg/ml (9.47mM)	Taking the 1 mL working solution as an example, add 50 μL of 70 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	369.42	Formula	C₂₃H₁₉N₃O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	905854-02-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	ARQ 197			Smiles	C1CC2=C3C(=CC=C2)C(=CN3C1)C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65

Mechanism of Action

Features	The first selective c-Met inhibitor to be advanced into human clinical trials.
Targets/IC₅₀/Ki	c-Met (Cell-free assay) 0.355 μM(Ki)
In vitro	ARQ-197 has been shown to prevent HGF/c-met induced cellular responses in vitro. This compound possesses antitumor activity; inhibiting proliferation of A549, DBTRG and NCI-H441 cells with IC50 of 0.38, 0.45, 0.29 μM. Treatment with this agent results in a decrease in phosphorylation of the MAPK signaling cascade and prevention of invasion and migration. In addition, ectopic expression of c-Met in NCI-H661, a cell line having no endogenous expression of c-Met, causes it to acquire an invasive phenotype that is also suppressed by this chemical. Although the addition of increasing concentrations of this inhibitor does not significantly affect the K_m of ATP, exposure of c-Met to 0.5 μM of this substance decreased the V_max of c-Met by approximately 3-fold. The ability of this molecule to decrease the V_max without affecting the Km of ATP confirmed that it inhibits c-Met through a non–ATP-competitive mechanism and may therefore account for its high degree of kinase selectivity. It prevents human recombinant c-Met with a calculated inhibitory constant K_i of approximately 355 nM. Although the highest concentration of ATP used is 200 μM, the potency of this compound against c-Met is not reduced by using concentrations of ATP up to 1 mM. It blocks c-Met phosphorylation and downstream c-Met signaling pathways. This chemical suppresses constitutive and ligand-mediated c-Met autophosphorylation and, by extension, c-Met activity, in turn leading to the inhibition of downstream c-Met effectors. Its induction of caspase-dependent apoptosis is increased in c-Met–expressing human cancer cells including HT29, MKN-45, and MDA-MB-231 cells.
Kinase Assay	c-Met SDS-PAGE in vitro kinase assay
Kinase Assay	Recombinant c-Met protein (100 ng) is preincubated with increasing concentrations of this compound for 30 minutes at room temperature. Following preincubation, 100 μM of poly-Glu-Tyr substrate and various concentrations of ATP containing 5 μCi of [γ-32P]ATP are added to the reaction mixture. The reaction is incubated for 5 minutes at room temperature and then stopped by the addition of 5 μL of SDS-polyacrylamide gel, reducing sample buffer. The samples are then loaded onto a 7.5% acrylamide gel and SDS-PAGE is performed. The phosphorylated poly-Glu-Tyr substrates are ultimately visualized by autoradiography. c-Met activity is quantified by densitometry.
In vivo	All three xenograft models treated with Tivantinib display reductions in tumor growth: 66% in the HT29 model, 45% in the MKN-45 model, and 79% in the MDA-MB-231 model. In these xenograft studies, no significant body weight changes following oral administration of this compound at 200 mg/kg are observed. Pharmacodynamically, the phosphorylation of c-Met in human colon xenograft tumors (HT29) is strongly inhibited by this chemical, as assessed by a dramatic reduction of c-Met autophosphorylation 24 hours after a single oral dose of 200 mg/kg of this agent. This same dosage in mice exhibits that tumor xenografts are exposed to sustained plasma levels of the compound, consistent with the observed pharmacodynamic inhibition of c-Met phosphorylation and inhibition of proliferation of c-Met harboring cancer cell lines. Plasma levels of the agent 10 hours after dosing are determined to be 1.3 μM, more than 3-fold above the biochemical inhibitory constant of this substance for c-Met. Therefore, it is able to suppress its target in vivo in the xenografted human tumor tissue. In conclusion, this inhibitor blocks the growth of c-Met-dependent xenografted human tumors.
References	[1] https://pubmed.ncbi.nlm.nih.gov/20484018/ [2] https://pubmed.ncbi.nlm.nih.gov/18511928/

Applications

Methods	Biomarkers	Images	PMID
Western blot	cMET / p-cMET / p-AKT / p-ERK / p-rpS6		23022995
Growth inhibition assay	Cell viability		23598276

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02150733	Completed	Hepatic Impairment\|Solid Tumor\|Cancer	Daiichi Sankyo\|Medpace Inc.	April 2014	Phase 1
NCT01892527	Completed	Colorectal Cancer Metastatic\|C-met Overexpression	Armando Santoro MD\|Istituto Clinico Humanitas	March 2013	Phase 2
NCT02049060	Completed	Malignant Pleural Mesothelioma\|Nonsquamous Nonsmall Cell Neoplasm of Lung	Armando Santoro MD\|Istituto Clinico Humanitas	January 2013	Phase 1\|Phase 2
NCT01755767	Completed	Hepatocellular Carcinoma	Daiichi Sankyo\|ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	December 27 2012	Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Are there any other solutions (apart from DMSO) I can dissolve it for in vivo experiment?

Answer:
S2753 This compound (ARQ 197) can be dissolved in 1% methylcellulose at 15 mg/ml as a suspension.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):